| Emitents | Grindeks, AS (5299006DWR32NKWM1O86) |
| Veids | Finanšu pārskati |
| Valoda | EN |
| Statuss | Publicēts |
| Versija | |
| Datums | 2009-08-07 09:28:04 |
| Versijas komentārs | |
| Teksts |
The financial statement of the first half-year of 2009 submitted by the joint-stock company “Grindeks” to “NASDAQ OMX Riga" testifies that the net profit of “Grindeks” concern in the first six months of this year amounted to 3.4 million lats, which has decreased by 32% in comparison with the first half-year of 2008, whereas the concern turnover reached 29.8 million lats within the first six months of the year, and it is 2.1 million lats or 6.6% less than in the first half-year of 2008. Chairman of the Board of “Grindeks” Janis Romanovskis: “Our activity is characterized by several “Grindeks” administration and operation factors – clear activity principles of management team and loyal shareholders interested in development of the company; efficient and qualitative original product Mildronate® and its successful sale, as well as constant entering into new markets and activity diversification of the company. In the situation when decline is observed within all pharmaceutical markets, we look at the results objectively and use our strong points, as well as the stable financial situation of the company which provides a good base for further investments and development.” In the first half-year of 2009 the sales volume of “Grindeks” final dosage forms amounted to 27.3 million lats; while export volume to CIS countries which are the main markets of final dosage forms reached 24.3 million lats. Taking into account the global economic recession affecting the pharmacy sector all over the world, including Russia and the rest CIS countries, a general decline in demand for medications is observed. In spite of that, in the first half-year of 2009 the sales volume in the rest CIS countries remained at the level of 2008. The sales volume in Russia in the first half-year of 2009 was by 2.3 million lats less than in the first half-year of 2008 because influence of the storehouse reserves established by the pharmaceutical company OJSC “Pharmstandart”, an exclusive distributor of Mildronate® in Russia, in the beginning of 2008 on dynamics of the sales volume still remains during the rest months of the year. Additionally, devaluation of local currencies in Russia and some other CIS countries against a lat, the value of which against euro remained fixed and maintained stability, had also some influence on the sales dynamic of the final dosage medication forms in monetary terms in the first half-year of the 2009. In the conditions of a tense economic situation the sales results in the Baltic States, as well as other European countries are positive by reaching the turnover of 3 million lats, which is by 6.5% more than in the first six months of the last year. Export of active pharmaceutical ingredients has also positively influenced “Grindeks” profit indicator, which amounted to 2.5 lats in the first half-year of 2009 and is by 0.2 million lats or 8.7% more than in the first half-year of 2008. Chairman of the Board of “Grindeks” Janis Romanovskis: “I have an optimistic view of the future – by taking all the advantages and responding to the changeable market situation in time, such a company as “Grindeks” will not only overcome obstacles to achieve the set goals but will also be one of the guides of economy of Latvia.” About “Grindeks” “Grindeks” is the leading pharmaceutical company in the Baltic States specalizing in the research, development, manufacturing and sales of original products, generic medications and active pharmaceutical ingredients. “Grindeks” concern consists of four subsidiary companies in Latvia, Estonia and Russia, as well as representative offices and representatives working in 14 countries. Products of the company are exported to more than 40 countries and amount to 96% of the total turnover. Main markets are the Baltic States, Russia, other CIS countries, Japan and the USA. JSC “Grindeks” shares are listed in the Official list of “NASDAQ OMX Riga”. Contacts: Laila Kļaviņa Head of the Communications Department JSC “Grindeks” Phone: (+371) 67083370, (+371) 29256012; fax: (+371) 67083505 E-mail: laila.klavina@grindeks.lv |
| Pielikumi |